CAMBRIDGE, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will attend the upcoming SIGnificant Investment Options in Healthcare Conference hosted by Susquehanna Financial Group on Thursday, March 1, 2007 at The Omni Berkshire Place in New York. Idenix will present a corporate overview, including an update of the company's commercialization activities and discovery and development programs at 2:00 p.m. EST. Idenix management will also participate in the panel discussion "HCV: What to Target - Proteases, Polymerases, or Replicases?" at 10:00 a.m. EST.
The live and archived audio only webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://ir.idenix.com/phoenix.zhtml?c=131556&p=irol- EventDetails&EventId=1478832 and the live and archived audio only webcast of the HCV panel discussion can be accessed at http://ir.idenix.com/phoenix.zhtml?c=131556&p=irol- EventDetails&EventId=1480968 (Due to the length of the URLs, please copy and paste into your browser). Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference. The company presentation will be available for download in PDF format in the "Investor Presentations" section of the Investor Center immediately following the presentation.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to http://www.idenix.com.
Idenix Pharmaceuticals' Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
Idenix Pharmaceuticals, Inc.CONTACT: Media, Teri Dahlman, +1-617-995-9905, or Investors, Amy Sullivan,+1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com//
